-
公开(公告)号：US08969325B2
公开(公告)日：2015-03-03
申请号：US13716862
申请日：2012-12-17
Applicant: AbbVie Inc.
Inventor： Michael J. Dart , Philip R. Kym , Eric A. Voight , Anurupa Shrestha , Jerome F. Daanen , Tammie K. Jinkerson , Ryan G. Keddy , Sridhar Peddi , Arthur Gomtsyan , Michael E. Kort , Gregory A. Gfesser , Kevin R. Woller , Derek W. Nelson
IPC: C07D405/12 , C07D215/38 , C07D239/80 , C07D413/12 , C07D491/052 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D413/14 , C07D215/227 , C07D265/36
CPC classification number: C07D405/12 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D215/227 , C07D215/38 , C07D239/80 , C07D265/36 , C07D413/12 , C07D413/14 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）的化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，G，Z，A，m，n和p如说明书中所定义。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20140080803A1
公开(公告)日：2014-03-20
申请号：US13658355
申请日：2012-10-23
Applicant: ABBVIE INC.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt , Eric A. Voight
IPC: A61K31/505 , A61K31/4418 , C07D213/34 , C07D213/38 , A61K31/444 , C07D239/26 , A61K31/4433 , C07D401/06 , A61K31/4427 , C07D405/08 , A61K31/443 , C07D417/08 , A61K31/4439 , A61K45/06 , A61K31/192 , C07D213/30
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（I）的TRPV3的调节剂，其中p为1,2,3或4，并且G1，X1，X2，X3，X4，X5，G2，Z1，Ra，Rb和u如 规格。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号：US20130131036A1
公开(公告)日：2013-05-23
申请号：US13658374
申请日：2012-10-23
Applicant: AbbVie Inc.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt , Eric A. Voight
IPC: A61K31/435 , A61K31/444 , C07D239/26 , A61K31/505 , C07D405/10 , A61K31/4433 , C07D405/06 , A61K31/443 , A61K31/4427 , C07D213/72 , C07D401/06 , A61K31/4545 , C07D215/14 , A61K31/47 , C07D221/04 , A61K31/4439 , A61K45/06 , C07D213/30
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（II）的TRPV3的调节剂：其中G1，X1，X2，X3，X4，X5，G2，Ra，Rb和u如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号：US08772500B2
公开(公告)日：2014-07-08
申请号：US13658374
申请日：2012-10-23
Applicant: AbbVie Inc.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt
IPC: C07D213/00 , C07D213/28 , C07D211/74 , C07D421/00 , C07D401/00
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（II）的TRPV3的调节剂：其中G1，X1，X2，X3，X4，X5，G2，Ra，Rb和u如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号：US08772499B2
公开(公告)日：2014-07-08
申请号：US13658355
申请日：2012-10-23
Applicant: AbbVie Inc.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt , Eric A. Voight
IPC: C07D213/00 , C07D213/28 , C07D211/74 , C07D421/00 , C07D401/00
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（I）的TRPV3的调节剂，其中p为1,2,3或4，并且G1，X1，X2，X3，X4，X5，G2，Z1，Ra，Rb和u如 规格。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
Patent Agency Ranking
公开(公告)号：US20130172334A1
公开(公告)日：2013-07-04
申请号：US13716862
申请日：2012-12-17
Applicant: AbbVie Inc.
Inventor： Michael J. Dart , Philip R. Kym , Eric A. Voight , Anurupa Shrestha , Jerome F. Daanen , Tammie K. Jinkerson , Ryan G. Keddy , Sridhar Peddi , Arthur Gomtsyan , Michael E. Kort , Gregory A. Gfesser , Kevin R. Woller , Derek W. Nelson
IPC: C07D405/12 , A61K31/192 , C07D239/80 , C07D413/12 , A61K31/4704 , C07D491/052 , A61K31/517 , A61K31/4709 , A61K31/538 , A61K45/06 , C07D215/38
CPC classification number: C07D405/12 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D215/227 , C07D215/38 , C07D239/80 , C07D265/36 , C07D413/12 , C07D413/14 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）的化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，G，Z，A，m，n和p如说明书中所定义。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20130158067A1
公开(公告)日：2013-06-20
申请号：US13716837
申请日：2012-12-17
Applicant: AbbVie Inc.
Inventor： Kevin R. Woller , Gregory A. Gfesser , Huaqing Liu , Jerome F. Daanen , Eric A. Voight , Irene I. Drizin , Anurupa Shrestha , Kathleen H. Mortell , Philip R. Kym , Michael E. Kort , Arthur Gomtsyan
IPC: C07D311/04 , A61K45/06 , A61K31/192 , C07D311/96 , A61K31/436 , A61K31/47 , C07C275/30 , A61K31/17 , C07C275/32 , C07D491/052 , A61K31/353 , C07D215/46
CPC classification number: C07D311/04 , A61K31/17 , A61K31/192 , A61K31/353 , A61K31/436 , A61K31/47 , A61K45/06 , C07C275/30 , C07C275/32 , C07D215/42 , C07D215/46 , C07D311/68 , C07D311/70 , C07D311/96 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，Rz，A，m，n，p，q，s和位置a和b如本说明书中所定义 。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20240158368A1
公开(公告)日：2024-05-16
申请号：US18379351
申请日：2023-10-12
Applicant: AbbVie Inc.
Inventor： David A. Degoey , Michael R. Schrimpf , David J. Hardee , Jacob Ludwig , Eric R. Miller , Timothy R. Hodges , Alberto Munoz , Sarah J. Perlmutter , Huan-Qiu X. Li , Alvin Jang , Elizabeth L. Noey , Gregory A. Gfesser , Edgars Jecs , Robert G. Schmidt , Justin D. Dietrich , Xenia B. Searle , Boguslaw P. Nocek , Andrew Bogdan
IPC: C07D401/12 , A61P31/14
CPC classification number: C07D401/12 , A61P31/14
Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.
-
公开(公告)号：US20150353550A1
公开(公告)日：2015-12-10
申请号：US14715330
申请日：2015-05-18
Applicant: AbbVie Inc.
Inventor： Michael R. Schrimpf , Chih-Hung Lee , Tao Li , Gregory A. Gfesser , Kathleen H. Mortell , Ramin Faghih , Diana L. Nersesian , Kevin B. Sippy , William H. Bunnelle , Marc Scanio , Lei Shi , Murali Gopalakrishnan , Diana L. Donnelly-Roberts , Min Hu
IPC: C07D471/18
CPC classification number: G01N33/5058 , C07D471/18 , C07D487/10 , C07D487/18 , G01N33/6896 , G01N2800/28 , G01N2800/30
Abstract: The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.
Abstract translation: 本申请涉及式（I），（II），（III），（IV），（V）或（VI）的吲哚和二氢吲哚衍生物，其中a，R1，R2，R3，R4，R5， V，W，X，Y和Z如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。
-
公开(公告)号：US08859584B2
公开(公告)日：2014-10-14
申请号：US13716837
申请日：2012-12-17
Applicant: AbbVie Inc.
Inventor： Kevin R. Woller , Gregory A. Gfesser , Huaqing Liu , Jerome F. Daanen , Eric A. Voight , Irene I. Drizin , Anurupa Shrestha , Kathleen H. Mortell , Philip R. Kym , Michael E. Kort , Arthur Gomtsyan
IPC: A61K31/44 , A61K31/35 , A61K31/47 , A61K31/17 , C07D215/46 , C07D498/02 , C07D311/68 , A61K45/06 , C07D311/96 , C07D311/04 , C07C275/30 , A61K31/192 , C07D311/70 , A61K31/353 , C07D491/052 , A61K31/436 , C07D215/42 , C07C275/32
CPC classification number: C07D311/04 , A61K31/17 , A61K31/192 , A61K31/353 , A61K31/436 , A61K31/47 , A61K45/06 , C07C275/30 , C07C275/32 , C07D215/42 , C07D215/46 , C07D311/68 , C07D311/70 , C07D311/96 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，Rz，A，m，n，p，q，s和位置a和b如本说明书中所定义 。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.032 seconds)
